Tvardi Therapeutics Inc(TVRD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 7:02 AM ET (Korea 11/6 21:02)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.78 | Insider Own | 24.71% | Shs Outstand | 13.3M | Perf Week | 0.17% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 1.96% | Insider Trans | - | Shs Float | 10.0M | Perf Month | -21.41% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.57 | Inst Own | 16.91% | Short Float | 3.74% | Perf Quarter | -53.77% |
| Income | -0.03B | P/S | - | EPS this Y | 31.66% | Inst Trans | -12.27% | Short Ratio | 2.12 | Perf Half Y | -79.47% |
| Sales | 0.00B | P/B | 0.97 | EPS next 5Y | 1.03% | ROA | -85.08% | Short Interest | 0.38M | Perf YTD | -79.9% |
| Book/sh | 0.89 | P/C | 0.73 | EPS past 3/5Y | 61.55% - | ROE | -126.19% | 52W High | -84.81% ($5.69) | Perf Year | -79.51% |
| Cash/sh | 1.18 | P/FCF | - | Sales past 3/5Y | - | ROIC | -310.13% | 52W Low | 11.85% ($0.77) | Perf 3Y | -98.22% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.57% | Gross Margin | - | Volatility(W/M) | 11.77% 9.4% | Perf 5Y | -99.87% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -99.67% |
| Dividend Ex-Date | - | Quick Ratio | 1.87 | EPS Q/Q | 31.47% | Profit Margin | - | RSI (14) | 34.99 | Recom | 1.78 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | - | SMA20 | -7.64% ($0.93) | Beta | 0.35 | Target Price | $9.62 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/14 | SMA50 | -33.57% ($1.29) | Rel Volume | 1 | Prev Close | $0.86 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 2.04% - | SMA200 | -67.79% ($2.67) | Avg Volume(3M) | 0.18M | Price | $0.86 |
| IPO | 2014/1/31 | Option/Short | Yes/Yes | Trades | 385 | Volume | 177,138 | Change | 0.36% |
A clinical-stage biotech developing oral small-molecule therapies targeting STAT3 protein. Its lead candidate, TTI-101 for hepatocellular carcinoma (HCC), has shown positive signals in Phase 2 trials and has received both FDA Orphan Drug and Fast Track designations.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
TVRD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #492 of 597 in the industry
Based on market cap of $12M.
GUTS#491 Fractyl Health Inc $12M PER - TVRD#492 Tvardi Therapeutics Inc $12M PER - 
HIND#493 Vyome Holdings Inc $11M PER - 
PBM#494 Psyence Biomedical Ltd $11M PER - 
PASG#495 Passage Bio Inc $11M PER - 
FAQ
What kind of company is TVRD?
TVRD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TVRD?
The market cap of TVRD is approximately $12M, ranking 5,370 within its sector.
What is the 52-week high and low for TVRD?
TVRD has recorded a 52-week high of $5.69 and a low of $0.77.
